Skip to main content

Advertisement

Table 3 Univariate analysis of predictive factors for overall and progression-free survival

From: Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer

  Overall Survival Progression-Free Survival
Characteristic HR (95% CI) P value HR (95% CI) P Value
Age, years
≥ 74 1    
< 74 1.87 (0.93–3.78) 0.080 1.42 (0.83–2.44) 0.196
Sex
Male 1    
Female 0.93 (0.48–1.82) 0.875 0.86 (0.51–1.47) 0.588
COPD stage
0–II 1    
III–IV 0.75 (0.37-1.54) 0.413 0.66 (0.37-1.17) 0.594
History of other type of cancer
Yes 1    
No 1.55 (0.78–3.09) 0.211 1.29 (0.74–2.24) 0.374
ECOG performance status
0–1 1    
2–3 2.03 (1.04–3.95) 0.037 1.68 (0.99–2.85) 0.050
Lung cancer stage
IA (T1) 1    
IB (T2) 1.28 (0.53–3.08) 0.586 1.11 (0.54–2.27) 0.776
Lung cancer histology
Non-squamous 1    
Squamous 1.16 (1.01–1.34) 0.043 1.09 (0.97–1.22) 0.173
Staging PET SUVmax
< 6.2 1    
≥ 6.2 2.10 (1.01-4.33) 0.028 1.81 (1.05–3.10) 0.032
Gross tumor volume, cm3
< 9.6 1    
≥ 9.6 1.55 (0.79–3.05) 0.204 1.42 (0.84–2.42) 0.195
Disease status
Medically inoperable 1    
Operable 0.36 (0.14–0.94) 0.036 0.51 (0.26–1.02) 0.055
Tumor location
Peripheral 1    
Central 0.97 (0.34–2.76) 0.954 0.89 (0.35–2.25) 0.809
Radiation pneumonitis
No 1    
Yes 1.19 (0.65–2.16) 0.571 0.92 (0.43–1.94) 0.819
  1. Abbreviations: HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; PET, positron emission tomography; SUVmax, maximum standardized uptake value.